<p>Editas Medicine, Inc.（纳斯达克代码：EDIT - 获取免费报告）首席执行官 Gilmore Neil O'neill 于 12 月 3 日星期三出售了 5,603 股公司股票，交易价格为每股平均 2.15 美元，总交易额为 12,046.45 美元。出售完成后，首席执行官直接持有公司 269,087 股股票，价值 578,537.05 美元。这代表其持股比例减少了 2.04%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。</p>
<p>获取 <strong>Editas Medicine</strong> 的提醒：</p>
<h2>Editas Medicine 股票上涨 2.5%</h2>
<ul>
<li>2 只基因编辑股票正在重塑遗传疾病治疗</li>
</ul>
<p>在周四的午盘交易中，纳斯达克：EDIT 上涨 0.06 美元，达到 2.43 美元。该公司的交易量为 1,570,206 股，而其平均交易量为 2,730,958 股。该股票的 50 日移动平均价格为 3.12 美元，200 日移动平均价格为 2.70 美元。Editas Medicine, Inc.的 52 周最低价为 0.91 美元，52 周最高价为 4.54 美元。该公司的市值为 2.3722 亿美元，市盈率为-1.02，贝塔值为 2.44。</p>
<p>Editas Medicine（纳斯达克：EDIT - 获取免费报告）最近一次发布季度财报是在 11 月 10 日星期一。该公司报告季度每股收益（EPS）为-0.28 美元，超出分析师一致预期的-0.38 美元，超出幅度为 0.10 美元。该季度的收入为 754 万美元，而分析师预期为 495 万美元。Editas Medicine 的股本回报率为-277.29%，净利润率为-430.84%。作为一个整体，研究分析师预测 Editas Medicine, Inc.在本年度的每股收益将为-2.71 美元。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
<p>一些券商最近对 EDIT 发布了报告。HC Wainwright 在 9 月 5 日星期五的研究报告中重申了 “买入” 评级，并将 Editas Medicine 的目标价设定为 5.00 美元。富国银行在 9 月 3 日星期三的研究报告中将 Editas Medicine 的目标价从 3.00 美元上调至 4.00 美元，并给予该公司 “持平” 评级。Chardan Capital 在 11 月 13 日星期四的研究报告中将 Editas Medicine 的评级从 “持有” 上调至 “强力买入”。Wall Street Zen 在 9 月 26 日星期五的研究报告中将 Editas Medicine 的评级从 “卖出” 上调至 “持有”。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Editas Medicine 的 “卖出（e+）” 评级。有两位投资分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，五位给予 “持有” 评级，二位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价为 4.29 美元。</p>
<p><strong>查看我们最新的 EDIT 股票分析</strong></p>
<h2>Editas Medicine 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近买入和卖出了该股票的股份。CIBC Bancorp USA Inc.在第三季度购买了 Editas Medicine 的新股份，价值约 57,000 美元。Jacobs Levy Equity Management Inc.在第三季度将其在 Editas Medicine 的持股增加了 761.7%。Jacobs Levy Equity Management Inc.现在拥有 800,023 股公司股票，价值 2,776,000 美元，此前在上个季度又购买了 707,181 股。加拿大人寿保险公司在第三季度将其在 Editas Medicine 的股份增加了 43.3%。加拿大人寿保险公司现在拥有 45,754 股公司股票，价值 161,000 美元，此前在上个季度又购买了 13,816 股。XTX Topco Ltd 在第三季度将其在 Editas Medicine 的股份增加了 95.7%。XTX Topco Ltd 现在拥有 260,113 股公司股票，价值 903,000 美元，此前在上个季度又购买了 127,176 股。最后，俄亥俄州公共雇员退休系统在第三季度购买了 Editas Medicine 的新股份，价值约 262,000 美元。对冲基金和其他机构投资者持有该公司 71.90% 的股份。</p>
<h2>关于 Editas Medicine</h2>
<p>（获取免费报告）</p>
<p>Editas Medicine, Inc.是一家临床阶段的基因组编辑公司，专注于开发变革性的基因治疗药物，以治疗一系列严重疾病。它开发了一种基于 CRISPR 技术的专有基因编辑平台。该公司正在开发 EDIT-101，目前正在进行 Leber 先天性黑朦的 1/2 期 BRILLIANCE 试验；以及 reni-cel，一种用于治疗镰状细胞病和输血依赖性β-地中海贫血的临床开发基因编辑药物。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Editas Medicine</li>
<li>复利是如何计算的？</li>
<li>利用 2026 年人工智能基础设施收益的高增长 ETF</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>强劲的季度，疲软的反应：为什么 GitLab 的股票下跌</li>
<li>股息支付比率计算器</li>
<li>特斯拉开始 12 月的三个迹象</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Editas Medicine 吗？</h2>
<p>在考虑 Editas Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Editas Medicine 并不在名单上。</p>
<p>虽然 Editas Medicine 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

EDIT

<p>Editas Medicine 首席执行官 Gilmore Neil O'neill 出售了 5,603 股，交易金额为 12,046.45 美元，减少了 2.04% 的持股比例。出售后，他持有 269,087 股，价值 578,537.05 美元。该交易已在 SEC 文件中披露。Editas 股票上涨 2.5%，报 2.43 美元，市值为 2.3722 亿美元。分析师的评级不一，平均目标价为 4.29 美元。机构投资者持有 71.90% 的股份</p>

<p>Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $2.15, for a total transaction of $12,046.45. Following the completion of the sale, the chief executive officer directly owned 269,087 shares in the company, valued at $578,537.05. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>Editas Medicine, Inc.（纳斯达克代码：EDIT - 获取免费报告）首席执行官 Gilmore Neil O'neill 于 12 月 3 日星期三出售了 5,603 股公司股票，交易价格为每股平均 2.15 美元，总交易额为 12,046.45 美元。出售完成后，首席执行官直接持有公司 269,087 股股票，价值 578,537.05 美元。这代表其持股比例减少了 2.04%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。</p>
</div><p>Get <strong>Editas Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Editas Medicine</strong> 的提醒：</p>
</div><h2>Editas Medicine Stock Up 2.5%</h2>
<div class="lb-trans"><h2>Editas Medicine 股票上涨 2.5%</h2>
</div><ul>
<li>2 gene-editing stocks reshaping hereditary disease treatments</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票正在重塑遗传疾病治疗</li>
</ul>
</div><p>NASDAQ:EDIT traded up $0.06 during midday trading on Thursday, hitting $2.43. The company had a trading volume of 1,570,206 shares, compared to its average volume of 2,730,958. The stock's fifty day moving average price is $3.12 and its 200-day moving average price is $2.70. Editas Medicine, Inc. has a 52-week low of $0.91 and a 52-week high of $4.54. The company has a market capitalization of $237.22 million, a PE ratio of -1.02 and a beta of 2.44.</p>
<div class="lb-trans"><p>在周四的午盘交易中，纳斯达克：EDIT 上涨 0.06 美元，达到 2.43 美元。该公司的交易量为 1,570,206 股，而其平均交易量为 2,730,958 股。该股票的 50 日移动平均价格为 3.12 美元，200 日移动平均价格为 2.70 美元。Editas Medicine, Inc.的 52 周最低价为 0.91 美元，52 周最高价为 4.54 美元。该公司的市值为 2.3722 亿美元，市盈率为-1.02，贝塔值为 2.44。</p>
</div><p>Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.10. The firm had revenue of $7.54 million during the quarter, compared to analysts' expectations of $4.95 million. Editas Medicine had a negative return on equity of 277.29% and a negative net margin of 430.84%. As a group, research analysts forecast that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.</p>
<div class="lb-trans"><p>Editas Medicine（纳斯达克：EDIT - 获取免费报告）最近一次发布季度财报是在 11 月 10 日星期一。该公司报告季度每股收益（EPS）为-0.28 美元，超出分析师一致预期的-0.38 美元，超出幅度为 0.10 美元。该季度的收入为 754 万美元，而分析师预期为 495 万美元。Editas Medicine 的股本回报率为-277.29%，净利润率为-430.84%。作为一个整体，研究分析师预测 Editas Medicine, Inc.在本年度的每股收益将为-2.71 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
</div><p>A number of brokerages have recently issued reports on EDIT. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $5.00 price objective on shares of Editas Medicine in a research note on Friday, September 5th. Wells Fargo &amp; Company lifted their price objective on Editas Medicine from $3.00 to $4.00 and gave the company an &#34;equal weight&#34; rating in a research report on Wednesday, September 3rd. Chardan Capital upgraded shares of Editas Medicine from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, November 13th. Wall Street Zen upgraded Editas Medicine from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, September 26th. Finally, Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Editas Medicine in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of &#34;Hold&#34; and an average target price of $4.29.</p>
<div class="lb-trans"><p>一些券商最近对 EDIT 发布了报告。HC Wainwright 在 9 月 5 日星期五的研究报告中重申了 “买入” 评级，并将 Editas Medicine 的目标价设定为 5.00 美元。富国银行在 9 月 3 日星期三的研究报告中将 Editas Medicine 的目标价从 3.00 美元上调至 4.00 美元，并给予该公司 “持平” 评级。Chardan Capital 在 11 月 13 日星期四的研究报告中将 Editas Medicine 的评级从 “持有” 上调至 “强力买入”。Wall Street Zen 在 9 月 26 日星期五的研究报告中将 Editas Medicine 的评级从 “卖出” 上调至 “持有”。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Editas Medicine 的 “卖出（e+）” 评级。有两位投资分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，五位给予 “持有” 评级，二位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价为 4.29 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on EDIT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 EDIT 股票分析</strong></p>
</div><h2>Institutional Trading of Editas Medicine</h2>
<div class="lb-trans"><h2>Editas Medicine 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new stake in Editas Medicine during the 3rd quarter worth approximately $57,000. Jacobs Levy Equity Management Inc. grew its holdings in Editas Medicine by 761.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company's stock valued at $2,776,000 after buying an additional 707,181 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in Editas Medicine by 43.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 45,754 shares of the company's stock valued at $161,000 after purchasing an additional 13,816 shares in the last quarter. XTX Topco Ltd raised its position in shares of Editas Medicine by 95.7% during the 3rd quarter. XTX Topco Ltd now owns 260,113 shares of the company's stock valued at $903,000 after buying an additional 127,176 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Editas Medicine in the 3rd quarter valued at approximately $262,000. Hedge funds and other institutional investors own 71.90% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了该股票的股份。CIBC Bancorp USA Inc.在第三季度购买了 Editas Medicine 的新股份，价值约 57,000 美元。Jacobs Levy Equity Management Inc.在第三季度将其在 Editas Medicine 的持股增加了 761.7%。Jacobs Levy Equity Management Inc.现在拥有 800,023 股公司股票，价值 2,776,000 美元，此前在上个季度又购买了 707,181 股。加拿大人寿保险公司在第三季度将其在 Editas Medicine 的股份增加了 43.3%。加拿大人寿保险公司现在拥有 45,754 股公司股票，价值 161,000 美元，此前在上个季度又购买了 13,816 股。XTX Topco Ltd 在第三季度将其在 Editas Medicine 的股份增加了 95.7%。XTX Topco Ltd 现在拥有 260,113 股公司股票，价值 903,000 美元，此前在上个季度又购买了 127,176 股。最后，俄亥俄州公共雇员退休系统在第三季度购买了 Editas Medicine 的新股份，价值约 262,000 美元。对冲基金和其他机构投资者持有该公司 71.90% 的股份。</p>
</div><h2>About Editas Medicine</h2>
<div class="lb-trans"><h2>关于 Editas Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.</p>
<div class="lb-trans"><p>Editas Medicine, Inc.是一家临床阶段的基因组编辑公司，专注于开发变革性的基因治疗药物，以治疗一系列严重疾病。它开发了一种基于 CRISPR 技术的专有基因编辑平台。该公司正在开发 EDIT-101，目前正在进行 Leber 先天性黑朦的 1/2 期 BRILLIANCE 试验；以及 reni-cel，一种用于治疗镰状细胞病和输血依赖性β-地中海贫血的临床开发基因编辑药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Editas Medicine</li>
<li>How is Compound Interest Calculated?</li>
<li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Strong Quarter, Weak Reaction: Why GitLab Shares Dropped</li>
<li>Dividend Payout Ratio Calculator</li>
<li>3 Signs Tesla Is Starting December on the Front Foot</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Editas Medicine</li>
<li>复利是如何计算的？</li>
<li>利用 2026 年人工智能基础设施收益的高增长 ETF</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>强劲的季度，疲软的反应：为什么 GitLab 的股票下跌</li>
<li>股息支付比率计算器</li>
<li>特斯拉开始 12 月的三个迹象</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=EDIT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Editas Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Editas Medicine 吗？</h2>
</div><p>Before you consider Editas Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Editas Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Editas Medicine 并不在名单上。</p>
</div><p>While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Editas Medicine 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Editas Medicine（NASDAQ:EDIT）的首席执行官出售了价值 12,046.45 美元的股票